A Look at BioNTech (NasdaqGS:BNTX) Valuation Following Pfizer's Complete Stake Sale

Pfizer’s move to sell its remaining stake in BioNTech (NasdaqGS:BNTX) through an overnight block trade has grabbed investor attention. The stake sale signals Pfizer’s exit as an equity holder, even as the companies continue collaborating on vaccines.

See our latest analysis for BioNTech.

The Pfizer stake sale made headlines, but BioNTech’s year has been marked by more than just this event. The company recently boosted its revenue guidance after strong collaboration sales and has focused fresh attention on its cancer drug pipeline. Despite these announcements and a successful secondary share offering, recent insider selling and the shifting COVID-19 landscape have weighed on sentiment. As a result, while the share price has slipped nearly 11% so far in 2025, the total shareholder return over the past year is still positive at just over 3%. This underscores BioNTech’s resilience as momentum in the sector fluctuates.

If you’re curious what other healthcare innovators are doing right now, exploring See the full list for free. could give you a jump on emerging trends and opportunities.

With BioNTech’s share price slipping and analysts maintaining upside targets, investors face a key question: is the recent pullback a chance to buy into future growth, or is everything already priced in?

Most Popular Narrative: 23.5% Undervalued

With BioNTech closing at $103.09 and the most widely followed narrative setting fair value nearly $32 higher, market watchers have reason to dig deeper into the underlying drivers of this gap.

"Robust pipeline expansion in oncology, with multiple late-stage (Phase II/III) clinical trials for BNT327 and mRNA cancer immunotherapies across high-prevalence cancers (lung and breast), positions BioNTech to launch multiple new products, driving significant top-line revenue growth and enhancing earnings visibility over the next several years."

Read the complete narrative.

Why do analysts expect such ambitious revenue transformation despite recent volatility? There is a surprising financial leap powering this narrative, and it is built on multi-year shifts in profit margins and a bold industry forecast. See how these play out in the full story.

Result: Fair Value of $134.78 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent reliance on COVID-19 vaccine sales and delays or setbacks in key oncology trials could quickly undermine the current bullish outlook.

Find out about the key risks to this BioNTech narrative.

Build Your Own BioNTech Narrative

If you see the story going another way or want to dig deeper into the numbers yourself, you can shape your own perspective quickly. Do it your way.

A good starting point is our analysis highlighting 1 key reward investors are optimistic about regarding BioNTech.

Looking for more investment ideas?

Stay one step ahead and strengthen your portfolio by tapping into fresh opportunities you might otherwise miss. Get started on your next investment move:

• Spot income potential and secure attractive yields by evaluating these 16 dividend stocks with yields > 3%, which offers reliable payouts above 3%.
• Capitalize on untapped growth with these 879 undervalued stocks based on cash flows, a selection of stocks chosen for compelling value based on strong cash flows.
• Catch the AI wave early and follow these 25 AI penny stocks, companies with the potential to shape tomorrow’s digital world.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com